Influence of position and radiation technique on organs at risk in radiotherapy of rectal cancer

Abstract

The influence of the position and radiation technique on the organs at risk (OARs) in radiotherapy of rectal cancer was evaluated. The relationship between the volume of irradiated small bowel (VSB) and acute bowel toxicity was determined. A total of 97 cases of rectal cancer were retrospectively randomized to receive radiotherapy with the designated treatment positions and radiation plans. Among 64 patients in the supine position, 32 patients were given three-dimensional conformal radiotherapy (3DCR) and 32 patients were subjected to intensity-modulated radiation therapy (IMRT) respectively. The rest 33 patients were treated with 3DCRT in the prone position with a belly board. The VSB was calculated for doses from 5 to 45 Gy at an interval of 5 Gy. With prescription dose in planned target volume (PTV) of 50 Gy, the dose distribution, conformal index for PTV (CI_PTV), dose-volume histogram (DVH) of OARs, the correlation of VSB and the acute toxicity were compared. The results were shown as follows: (1) Among the 3 methods, there were no differences in PTV’s converge including V95 and D95; (2) For IMRT under a supine position, CI_PTV was closest to 1, the mean dose of small bowel decreased (P<0.05), and the mean VSB from V30 to V45 significantly decreased (P<0.05). (3) For 3DCRT with a belly board under a prone position, the mean dose and the mean VSB from 40 to 45 Gy were less than those for 3DCRT under a supine position (P<0.05); (4) Mean proportion of VSB was significantly greater in the patients experiencing diarrhea grade 2-4 than in those with diarrhea grade 0-1 at dose levels from V30 to V45 (P<0.05). It was concluded that for the radiotherapy of rectal cancer, IMRT technique might decrease the high-dose VSB to reduce the risk of acute injury. 3DCRT with a belly board under a prone position is superior to 3DCRT under a supine position, which could be a second choice for radiation of rectal cancer.

Keywords

rectal cancer / radiation / supine position / prone position / three-dimensional conformal radiotherapy / intensity-modulated radiation therapy / small bowel injury

References

[1] The NCCN guidelines on rectal cancer. Version 2. 2016. Retrieved from https://www.nccn.org/professionals/physician_ gls/f_guidelines.asp#rectal.

[2] BensonAB, VenookAP, Bekaii-SaabT, et al. . Rectal cancer, Version 2.2015. J Natl Compr Canc Netw, 2015, 13(6): 719-728 PMID: 26085388

[3] BrændengenM, TveitKM, HjermstadMJ, et al. . Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long term results from a phase ? study. Eur J Cancer, 2012, 48(6): 813-819 PMID: 21782418

[4] BrændengenM, TveitKM, BruheimK, et al. . Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized phase III study. Int J Radiat Oncol Biol Phys, 2011, 81(4): 1017-1024 PMID: 20932687

[5] RajeevKR, MenonSS, BeenaK, et al. . A comparative study of set up variations and bowel volumes in supine versus prone positions of patients treated with external beam radiation for carcinoma rectum. J Cancer Res Ther, 2014, 10(4): 937-941 PMID: 25579532

[6] MokH, CraneCH, PalmerMB, et al. . Intensity modulated radiation therapy (IMRT): differences in target volumes and improvement in clinically relevant doses to small bowel in rectal carcinoma. Radiat Oncol, 2011, 6: 63 PMID: 21651775 PMCID: 3121606

[7] RichettiA, FogliataA, ClivioA, et al. . Neo-adjuvant chemo-radiation of rectal cancer with volumetric modulated arc therapy: summary of technical and dosimetric features and early clinical experience. Radiat Oncol, 2010, 5: 14 PMID: 20170490 PMCID: 2838920

[8] JabbourSK, HashemSA, BoschW, et al. . Upper abdominal normal organ contouring guidelines and atlas: a Radiation Therapy Oncology Group consensus. Pract Radiat Oncol, 2014, 4(2): 82-89 PMID: 24890348

[9] DrzymalaM, HawkinsMA, HenrysAJ, et al. . The effect of treatment position, prone or supine, on dose-volume histograms for pelvic radiotherapy in patients with rectal cancer. Br J Radiol, 2009, 82: 321-327 PMID: 19188240

[10] NijkampJ, DoodemanB, MarijnenC, et al. . Bowel exposure in rectal cancer IMRT using prone, supine, or a belly board. Radiother Oncol, 2012, 102(1): 22-29 PMID: 21723637

[11] SamuelianJM, CallisterMD, AshmanJB, et al. . Reduced acute bowel toxicity in patients treated with intensity-modulated radiotherapy for rectal cancer. Int J Radiat Oncol Biol Phys, 2012, 82(5): 1981-1987 PMID: 21477938

[12] FrøsethTC, StrickertT, SolliKS, et al. . A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients. Radiat Oncol, 2015, 10: 217 PMID: 26508131 PMCID: 4624657

[13] Wiesendanger-WittmerEM, SijtsemaNM, MujisCT, et al. . Systematic review of the role of a belly board device in radiotherapy delivery in patients with pelvic malignancies. Radiother Oncol, 2012, 102(3): 325-334 PMID: 22364650

[14] LinLL, HertanL, RenganR, et al. . Effect of body mass index on magnitude of setup errors in patients treated with adjuvant radiotherapy for endometrial cancer with daily image guidance. Int J Radiat Oncol Biol Phys, 2012, 83(2): 670-675 PMID: 22208974

[15] YoonWS, YangDS, LeeJA, et al. . Risk factors related to interfractional variation in whole pelvic irradiation for locally advanced pelvic malignancies. Strahlenther Onkol, 2012, 188(5): 395-403 PMID: 22318329

[16] TuralD, OzturkM, SelcukbiricikF, et al. . Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer. J Buon, 2013, 18(2): 385-390 PMID: 23818350

[17] WygodaM, RottenbergY, KadouriL, et al. . Preoperative radiotherapy and concurrent chemotherapy with bolus 5-fluorouracil for rectal cancer: a prospective analysis of 98 patients. Tumori, 2010, 96(5): 709-712 PMID: 21302617

[18] AscheleC, CioniniL, LonardiS, et al. . Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol, 2011, 29(20): 2773-2780 PMID: 21606427

[19] RobertsonJM, SöhnM, YanD. Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model. Int J Radiat Oncol Biol Phys, 2010, 77(1): 66-72 PMID: 19665323

[20] ReisT, KhazzakaE, WelzelG, et al. . Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhea. Radiat Oncol, 2015, 10: 30 PMID: 25636703 PMCID: 4324657

[21] BanerjeeR, ChakrabortyS, NygrenI, et al. . Small bowel dose parameters predicting grade = 3 acute toxicity in rectal cancer patients treated with neoadjuvant chemoradiation: an independent validation study comparing peritoneal space versus small bowel loop contouring techniques. Int J Radiat Oncol Biol Phys, 2013, 85(5): 1225-1231 PMID: 23182394